EMEA-001806-PIP03-18
Key facts
Invented name |
Kyprolis
|
Active substance |
carfilzomib
|
Therapeutic area |
Haematology-Hemostaseology
|
Decision number |
P/0171/2019
|
PIP number |
EMEA-001806-PIP03-18
|
Pharmaceutical form(s) |
Powder for solution for infusion
|
Condition(s) / indication(s) |
Treatment of Multiple Myeloma
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Amgen Europe B.V
Tel.: +44 (0)1223 420305 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|